Dendritic cell based tumor vaccination in prostate and renal cell cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Draube, Andreas ^a   Klein González, Nela ^a,b   Mattheus, Stefanie ^a   Brillant, Corinne ^a   Hellmich, Martin ^b   Engert, Andreas ^a   von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; FLUOROURACIL; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; PA 2024; UNCLASSIFIED DRUG; CANCER VACCINE;

ADJUVANT THERAPY; ANTIGEN PRESENTATION; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DENSITY; CELL MATURATION; CELL TYPE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG QUALITY; HUMAN; HUMORAL IMMUNITY; KIDNEY CARCINOMA; LYMPH NODE; META ANALYSIS; MONOCYTE; PROSTATE CANCER; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; MALE; PROSTATE TUMOR;

CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; QUALITY CONTROL;

EID: 79955451697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018801     Document Type: Review

References (89)

1. Coley WB, (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res pp. 3-11.
2. Ehrlich P, (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5: 273-290.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
5. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K, (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356: 1795-1799.
6. Steinman RM, Cohn ZA, (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137: 1142-1162.
7. Cranmer LD, Trevor KT, Hersh EM, (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53: 275-306.
8. Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK, (2006) Dendritic cell-based immunotherapy. Int Rev Immunol 25: 377-413.
9. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, et al. (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56: 1513-1537.
10. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, et al. (2009) Improving the efficacy of cancer immunotherapy. Eur J Cancer 45: 1424-1431.
11. Verra N, de Jong D, Bex A, Batchelor D, Dellemijn T, et al. (2005) Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 48: 527-533.
12. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594-599.
13. Asemissen AM, Brossart P, (2009) Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother 58: 1169-1174.
14. Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H, (2007) Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 121: 467-473.
15. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, et al. (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53: 694-708.
16. Berntsen A, Geertsen PF, Svane IM, (2006) Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50: 34-43.
17. Jahnisch H, Fussel S, Kiessling A, Wehner R, Zastrow S, et al. (2010) Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol 2010 517493: 517493.
18. Van Poppel H, Joniau S, Van Gool SW, (2009) Vaccine therapy in patients with renal cell carcinoma. Eur Urol 55: 1333-1342.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
20. Nagorsen D, Thiel E, (2006) Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12: 3064-3069.
21. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG, (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166: 4254-4259.
22. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML, (2000) Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 60: 829-833.
23. Murphy GP, Snow P, Simmons SJ, Tjoa BA, Rogers MK, et al. (2000) Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients. Prostate 42: 67-72.
24. Kraemer M, Hauser S, Schmidt-Wolf IG, (2010) Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. Anticancer Res 30: 2081-2086.
25. Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, et al. (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54: 663-670.
26. Avigan D, Vasir B, Gong J, Borges V, Wu Z, et al. (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10: 4699-4708.
27. Arroyo JC, Gabilondo F, Llorente L, Meraz-Rios MA, Sanchez-Torres C, (2004) Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol 24: 86-96.
28. Matsumoto A, Haraguchi K, Takahashi T, Azuma T, Kanda Y, et al. (2007) Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 14: 277-283.
29. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, et al. (2009) Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 35: 569-581.
30. Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, et al. (2006) [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma-a report of ten cases]. Ai Zheng 25: 625-630.
31. Putz T, Ramoner R, Gander H, Rahm A, Bartsch G, et al. (2004) Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis. J Clin Immunol 24: 653-663.
32. Lee D, (2003) Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for patients with hormone-refractory prostate cancer with a Gleason score &or = 7. Clin Prostate Cancer 2: 81-83.
33. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, et al. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089-3094.
34. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, et al. (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU International 94: 412-418.
35. Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, et al. (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53: 453-460.
36. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, et al. (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6: 2175-2182.
37. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, et al. (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167: 7150-7156.
38. Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, et al. (2006) Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66: 811-821.
39. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, et al. (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409-417.
40. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, et al. (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679.
41. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, et al. (2007) Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate 67: 500-508.
42. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
43. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, et al. (2005) Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 93: 749-756.
44. Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, et al. (2000) Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43: 59-62.
45. Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, et al. (2006) Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 55: 1033-1042.
46. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, et al. (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903.
47. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, et al. (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174: 3798-3807.
48. Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, et al. (2006) Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 119: 2428-2434.
49. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Bohme C, et al. (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55: 1524-1533.
50. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, et al. (2008) Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 31: 771-780.
51. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Voller MC, De Weijer K, et al. (2007) Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 30: 116-122.
52. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633.
53. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, et al. (2003) A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26: 412-419.
54. Holtl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, et al. (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8: 3369-3376.
55. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, et al. (2007) Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 125: 257-267.
56. Marten A, Flieger D, Renoth S, Weineck S, Albers P, et al. (2002) Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51: 637-644.
57. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, et al. (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 25: 500-508.
58. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, et al. (2009) Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 15: 4986-4992.
59. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, et al. (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63: 2127-2133.
60. Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, et al. (2007) Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol Rep 18: 665-671.
61. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, et al. (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918.
62. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ, (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10: 475-480.
63. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467.
64. Finn OJ, (2008) Cancer immunology. N Engl J Med 358: 2704-2715.
65. Rosenberg S, Yang J, Restifo N, (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
66. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
67. Steinman RM, Hawiger D, Nussenzweig MC, (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
68. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
69. Gabrilovich D, (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4: 941-952.
70. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, et al. (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15: 6267-6276.
71. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM, (2009) Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58: 1-14.
72. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, et al. (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30: 1-15.
73. Zhao B, Schwartz LH, Larson SM, (2009) Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 50: 239-249.
74. Schlom J, Gulley JL, Arlen PM, (2008) Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) 233: 522-534.
75. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, et al. (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198: 615-621.
76. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, et al. (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15: 2531-2540.
77. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
78. Steinman RM, Nussenzweig MC, (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 99: 351-358.
79. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, et al. (2003) Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18: 605-617.
80. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N, (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193: 233-238.
81. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, et al. (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63: 12-17.
82. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, et al. (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93: 243-251.
83. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, et al. (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9: 5091-5100.
84. von Andrian UH, Memper TR, (2003) Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3: 867-878.
85. Miyasaka M, Tanaka T, (2004) Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 4: 360-370.
86. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, et al. (2006) CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 107: 2786-2789.
87. Robert C, Klein C, Cheng G, Kogan A, Mulligan RC, et al. (2003) Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther 10: 1479-1486.
88. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, et al. (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9: 998-1008.
89. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A, (2008) Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother 57: 285-288.